Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Dec;38(12):2819-2827.
doi: 10.1007/s10554-022-02708-7. Epub 2022 Aug 22.

Impact of trans-stent gradient on outcome after PCI: results from a HAWKEYE substudy

Affiliations

Impact of trans-stent gradient on outcome after PCI: results from a HAWKEYE substudy

Andrea Erriquez et al. Int J Cardiovasc Imaging. 2022 Dec.

Abstract

To test whether quantitative flow ratio (QFR)-based trans-stent gradient (TSG) is associated with adverse clinical events at follow-up. A post-hoc analysis of the multi-center HAWKEYE study was performed. Vessels post-PCI were divided into four groups (G) as follows: G1: QFR ≥ 0.90 TSG = 0 (n = 412, 54.8%); G2: QFR ≥ 0.90, TSG > 0 (n = 216, 28.7%); G3: QFR < 0.90, TSG = 0 (n = 37, 4.9%); G4: QFR < 0.90, TSG > 0 (n = 86, 11.4%). Cox proportional hazards regression model was used to analyze the effect of baseline and prognostic variables. The final reduced model was obtained by backward stepwise variable selection. Receiver operating characteristic (ROC) was plotted and area under the curve (AUC) was calculated and reported. Overall, 449 (59.8%) vessels had a TSG = 0 whereas (40.2%) had TSG > 0. Ten (2.2%) vessel-oriented composite endpoint (VOCE) occurred in vessels with TSG = 0, compared with 43 (14%) in vessels with TSG > 0 (p < 0.01). ROC analysis showed an AUC of 0.74 (95% CI: 0.67 to 0.80; p < 0.001). TSG > 0 was an independent predictor of the VOCE (HR 2.95 [95% CI 1.77-4.91]). The combination of higher TSG and lower final QFR (G4) showed the worst long-term outcome while low TSG and high QFR showed the best outcome (G1) while either high TSG or low QFR (G2, G3) showed intermediate and comparable outcomes. Higher trans-stent gradient was an independent predictor of adverse events and identified a subgroup of patients at higher risk for poor outcomes even when vessel QFR was optimal (> 0.90).

Keywords: Angiography-based fractional flow reserve; Outcome; Percutaneous coronary intervention; Trans-stent gradient; Vessel-oriented composite endpoint.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: SB received research grant from Medis, SMT, Siemens, Insight Lifetech, GE and personal fees from Siemens and Insight Lifetech. GC received research grant from Boston Scientific, Medis, SMT, Siemens, Insight Lifetech. MT received research grant from Boston Scientific. BFU received research grant from Opsens.

SB received research grant from Medis, SMT, Siemens, Insight Lifetech, GE and personal fees from Siemens and Insight Lifetech. GC received research grant from Boston Scientific, Medis, SMT, Siemens, Insight Lifetech. MT received research grant from Boston.

Figures

Fig. 1
Fig. 1
Kaplan–Meier curves displaying cumulative VOCE risk according to vessel-QFR and TSG values. VOCE vessel oriented composite endpoint, QFR quantitative flow-ratio, TSG trans-stent gradient
Fig. 2
Fig. 2
Receiver-operating characteristic curve analysis of QFR-TSG ability to predict the occurrence of VOCE in the study population. VOCE vessel oriented composite endpoint, QFR quantitative flow-ratio, TSG trans-stent gradient, AUC area under the curve
Fig. 3
Fig. 3
Graph bar showing the percentage of VOCE at 1-year according to QFR and TSG values. VOCE vessel oriented composite endpoint, QFR quantitative flow-ratio, TSG trans-stent gradient

References

    1. Brugaletta S, Gomez-Lara J, Ortega-Paz L, et al. 10-year follow-up of patients with everolimus-eluting versus bare-metal stents after ST-segment elevation myocardial infarction. J Am Coll Cardiol. 2021;77(9):1165–1178. doi: 10.1016/J.JACC.2020.12.059. - DOI - PubMed
    1. Pavasini R, Biscaglia S, Barbato E, et al. Complete revascularization reduces cardiovascular death in patients with ST-segment elevation myocardial infarction and multivessel disease: systematic review and meta-analysis of randomized clinical trials. Eur Heart J. 2022 doi: 10.1093/eurheartj/ehz896. - DOI - PubMed
    1. Sabaté M, Brugaletta S, Cequier A, et al. Clinical outcomes in patients with ST-segment elevation myocardial infarction treated with everolimus-eluting stents versus bare-metal stents (EXAMINATION): 5-year results of a randomised trial. The Lancet. 2016;387(10016):357–366. doi: 10.1016/S0140-6736(15)00548-6. - DOI - PubMed
    1. von Birgelen C, Zocca P, Buiten RA, et al. Thin composite wire strut, durable polymer-coated (Resolute Onyx) versus ultrathin cobalt–chromium strut, bioresorbable polymer-coated (Orsiro) drug-eluting stents in allcomers with coronary artery disease (BIONYX): an international, single-blind, randomi. The Lancet. 2018;392(10154):1235–1245. doi: 10.1016/S0140-6736(18)32001-4. - DOI - PubMed
    1. Biscaglia S, Uretsky B, Barbato E, et al. Invasive coronary physiology after stent implantation: another step toward precision medicine. Cardiovasc Interv. 2021;14(3):237–246. - PubMed

LinkOut - more resources